NextCell Pharma AB
STO:NXTCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NextCell Pharma AB
Cash from Operating Activities
NextCell Pharma AB
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NextCell Pharma AB
STO:NXTCL
|
Cash from Operating Activities
-kr50.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Cash from Operating Activities
kr306.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Cash from Operating Activities
kr221.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Cash from Operating Activities
kr635m
|
CAGR 3-Years
0%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Cash from Operating Activities
kr8.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
33%
|
|
|
BioArctic AB
STO:BIOA B
|
Cash from Operating Activities
kr1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NextCell Pharma AB
Glance View
NextCell Pharma AB engages in the development of stem cell products. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2017-07-13. The firm is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
See Also
What is NextCell Pharma AB's Cash from Operating Activities?
Cash from Operating Activities
-50.9m
SEK
Based on the financial report for Dec 31, 2025, NextCell Pharma AB's Cash from Operating Activities amounts to -50.9m SEK.
What is NextCell Pharma AB's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-21%
Over the last year, the Cash from Operating Activities growth was -25%. The average annual Cash from Operating Activities growth rates for NextCell Pharma AB have been -12% over the past three years , -21% over the past five years .
